Medications for Hyperlipidemia

5 results

  • nexlizet

    (Bempedoic Acid and Ezetimibe)
    Esperion Therapeutics, Inc.
    NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet. It also reduces the risk of myocardial infarction and coronary revascularization in statin-intolerant patients at high cardiovascular risk.

  • praluent

    (alirocumab)
    Regeneron Pharmaceuticals, Inc.
    PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.

  • repatha

    (Evolocumab)
    Amgen Inc
    REPATHA is indicated for reducing the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. It also reduces LDL-C in adults with primary hyperlipidemia, including HeFH, and in pediatric patients aged 10 and older with HeFH or HoFH as an adjunct to diet and other therapies.

  • welchol

    (colesevelam hydrochloride)
    Cosette Pharmaceuticals, Inc.
    WELCHOL is indicated as an adjunct to diet and exercise for reducing elevated LDL-C in adults with primary hyperlipidemia and in boys and postmenarchal girls (10-17 years) with HeFH. It also improves glycemic control in adults with type 2 diabetes mellitus. Limitations apply for specific diabetes types.

  • zypitamag

    (Pitavastatin Magnesium)
    Medicure International Inc
    ZYPITAMAG is indicated as an adjunct to diet for reducing low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. Pediatric use information is available for LIVALO, but ZYPITAMAG does not include this due to marketing exclusivity rights.